OXYCODONE HYDROCHLORIDE (oxycodone hydrochloride) by Bayer is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 2010.
Drug data last refreshed Yesterday
Oxycodone hydrochloride is a full mu-opioid receptor agonist indicated for acute pain, chronic pain, and osteoarthritis. It is administered orally in capsule form and works by binding to opioid receptors in the CNS to produce analgesia without a ceiling effect. Dosing is titrated based on analgesic response and tolerability, with potential for respiratory and CNS depression at higher doses.
With LOE approaching and moderate competitive pressure (30), brand team size is likely static to declining, focusing on lifecycle extension and niche positioning.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Worked on OXYCODONE HYDROCHLORIDE at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This is a mature, legacy opioid product with minimal new job creation and heightened regulatory/reputational scrutiny in the opioid crisis context. Career opportunities are primarily in defensive commercial strategy, managed care navigation, and transition planning rather than growth or innovation.